Age-dependent pathogenic profiles of enterotoxigenic Escherichia coli diarrhea in Bangladesh DOI Creative Commons
Marjahan Akhtar, Yasmin Ara Begum, Sadia Rahman

et al.

Frontiers in Public Health, Journal Year: 2024, Volume and Issue: 12

Published: Dec. 12, 2024

Background Age plays a significant role in susceptibility to enterotoxigenic Escherichia coli (ETEC) infections, yet the distribution of ETEC virulence factors across age groups remains understudied. This study investigated differential pathogenic profiles various groups, emphasizing importance selecting potential antigens tailored infection patterns infants and adults Bangladesh. Methods utilized icddr,b’s 2% systematic hospital surveillance data diarrheal patients ( n = 14,515) from 2017 2022 examine age-specific pathogenesis clinical manifestations infections. Results In total was identified 1,371 (9.4%) samples. ETEC-associated diarrhea higher children aged 0–2 years decreased significantly 3–17 group. Among all cases, 56% were p 0.0079) with severe dehydration. Distinct toxin types colonization (CFs) observed: heat labile (LT)-associated infections < 0.0001), while stable (ST)-associated-ETEC prevalent ages. Adults exhibited rates strains secreting both toxins. A high prevalence antimicrobial resistance among strains, particularly pediatric observed against commonly used antibiotics such as azithromycin line similar specific profiles. The most common CFs CFA/I, CS3, CS5, CS6, CS21. CFA/I positive more 0.001), CS5 CS6 0.0001). Conclusion findings provide valuable insights into epidemiology, pathogenesis, manifestations. These observations imply that age-related differences host-pathogen interactions exist for this may influence development targeted vaccines or therapeutics use populations.

Language: Английский

Use of an ETEC Proteome Microarray to Evaluate Cross-Reactivity of ETVAX® Vaccine-Induced IgG Antibodies in Zambian Children DOI Creative Commons
Cynthia Mubanga, Michelo Simuyandi, Kapambwe Mwape

et al.

Vaccines, Journal Year: 2023, Volume and Issue: 11(5), P. 939 - 939

Published: May 4, 2023

Developing a broadly protective vaccine covering most ETEC variants has been elusive. The clinically advanced candidate yet is an oral inactivated (ETVAX®). We report on the use of proteome microarray for assessment cross-reactivity anti-ETVAX® IgG antibodies against over 4000 antigens and proteins. evaluated 40 (pre-and post-vaccination) plasma samples from 20 Zambian children aged 10–23 months that participated in phase 1 trial investigating safety, tolerability, immunogenicity ETVAX® adjuvanted with dmLT. Pre-vaccination revealed high responses to variety proteins including classical (CFs LT) non-classical antigens. Post-vaccination reactivity CFA/I, CS3, CS6, LTB was stronger than baseline among vaccinated compared placebo group. Interestingly, we noted significantly post-vaccination three non-vaccine proteins: CS4, CS14, PCF071 (p = 0.043, p 0.028, 0.00039, respectively), suggestive cross-reactive CFA/I. However, similar were observed group, indicating need larger studies. conclude useful tool antibody numerous antigens, especially because it may not be practicable include all single vaccine.

Language: Английский

Citations

8
Developments in oral enterotoxigenic Escherichia coli vaccines DOI Creative Commons

Ann‐Mari Svennerholm,

Anna Lundgren

Current Opinion in Immunology, Journal Year: 2023, Volume and Issue: 84, P. 102372 - 102372

Published: July 29, 2023

Enterotoxigenic Escherichia coli (ETEC) is a leading cause of diarrhea in children developing countries and travelers. WHO has affirmed ETEC as priority vaccine target, but there no licensed available yet. We here describe recent, promising developments different live, inactivated, subunit candidate vaccines expressing or containing nontoxic enterotoxin and/or colonization factor antigens with focus on oral vaccines. Many the have been tested clinical trials for safety immunogenicity some them also protective efficacy field challenge studies.

Language: Английский

Citations

8
Modern vaccine development via reverse vaccinology to combat antimicrobial resistance DOI
Asuka Joy Tobuse, Ang Chee Wei, Keng Yoon Yeong

et al.

Life Sciences, Journal Year: 2022, Volume and Issue: 302, P. 120660 - 120660

Published: May 25, 2022

Language: Английский

Citations

9
Genomic insights into the 2022–2023Vibrio choleraeoutbreak in Malawi DOI Creative Commons
Chrispin Chaguza, Innocent Chibwe, David Chaima

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2023, Volume and Issue: unknown

Published: June 12, 2023

Abstract Malawi is experiencing its deadliest Vibrio cholerae ( Vc ) outbreak following devastating cyclones, with >58,000 cases and >1,700 deaths reported between March 2022 May 2023. Here, we use population genomics to investigate the attributes origin of 2022– 2023 isolates. Our results demonstrate predominance ST69 seventh cholera pandemic El Tor (7PET) strains expressing O1 Ogawa (∼80%) serotype followed by Inaba (∼16%) typical non-outbreak-associated non-O1/non-ST69 serotypes (∼4%). Phylogenetic reconstruction current historical isolates from Malawi, together global isolates, suggested originated Asia. The unique antimicrobial resistance virulence profiles 2022–2023 notably acquisition ICE GEN /ICEVchHai1/ICEVchind5 SXT/R391-like integrative conjugative elements a CTXφ prophage, which caused ctxB3 ctxB7 genotype shift, support importation hypothesis. These data suggest that recent strains, coupled climatic changes, may explain magnitude in Malawi.

Language: Английский

Citations

5
Application of a Novel Proteomic Microarray Reveals High Exposure to Diarrhoeagenic Escherichia coli among Children in Zambia Participating in a Phase I Clinical Trial DOI Creative Commons
Kapambwe Mwape, Cynthia Mubanga, Obvious Nchimunya Chilyabanyama

et al.

Microorganisms, Journal Year: 2024, Volume and Issue: 12(3), P. 420 - 420

Published: Feb. 20, 2024

Diarrhoeagenic E. coli (DEC) significantly contributes to the burden of diarrhoea among children. Currently, there is no approved vaccine against DEC, but several vaccines enterotoxigenic (ETEC) pathotype are in advanced clinical trial stages, including ETVAX® vaccine, undergoing evaluation Zambia. This study reports on reactivity antibodies from and placebo recipients a phase I proteins derived other than ETEC. Plasma samples collected at two time points (prior any vaccination post-third dose vaccination) 16 vaccinated 4 participants 1 examining safety, tolerability, immunogenicity with dmLT adjuvant were evaluated for IgG response antigens ETEC using Pan-DEC protein microarray. was first field application novel pan-DEC array as new tool assessing antigenic breadth antibody responses induced by ETVAX well assess early life exposure DEC pathotypes bacterial enteric pathogens. We observed that plasma obtained had high Ipa, SseC EspB proteins. These findings suggest pathogens, like EPEC, EHEC, EAEC EIEC addition ETEC, Zambian population. immunological observations consistent results recent epidemiological studies etiology diarrheal disease infants young children

Language: Английский

Citations

1
Immunoinformatics-driven design and computational analysis of a multiepitope vaccine targeting uropathogenic Escherichia coli DOI
Hina Khalid, Sergey Shityakov

In Silico Pharmacology, Journal Year: 2024, Volume and Issue: 13(1)

Published: Dec. 21, 2024

Language: Английский

Citations

1
Dual-Use Vaccine for Diarrhoeal Diseases: Cross-Protective Immunogenicity of a Cold-Chain-Free, Live-Attenuated, Oral Cholera Vaccine against Enterotoxigenic Escherichia coli (ETEC) Challenge in BALB/c Mice DOI Creative Commons
Tew Hui Xian, Subramani Parasuraman, Manickam Ravichandran

et al.

Vaccines, Journal Year: 2022, Volume and Issue: 10(12), P. 2161 - 2161

Published: Dec. 16, 2022

In low- and middle-income countries, diarrhoeal diseases are the second most common cause of mortality in children, mainly caused by enterotoxin-producing bacteria, such as Shigella, Vibrio, Salmonella, Escherichia coli. Cholera traveller's diarrhoea Vibrio cholerae (O1 O139 serogroups) enterotoxigenic coli (ETEC), respectively. The cholera toxin (CT) produced V. heat-labile enterotoxin (LT) ETEC closely related structure, function, immunological response to them. There is no exclusive vaccine for ETEC; however, vaccines based on CT-B component elicit a short-term cross-protection against infection. this context, cross-protective efficacy MyCholTM, prototype cold-chain-free, live-attenuated, oral was evaluated BALB/c mice. 100% lethal dose (LD100) 109 CFU/mL H10407 strain used challenge studies. mice immunised with MyChol™ survived producing anti-CT antibodies, which cross-neutralised LT body weight loss sign diarrhoea. Compared unimmunised mice, elicited neutralising antitoxin that markedly decreased colonisation fluid accumulation intestines. recorded higher antibody titres, including IgG, anti-LT anti-CT-B anti-LTB IgG. Only two-fold rise anti-CT/CT-B/LT/LT-B IgA serum samples from No bactericidal antibodies were detected. This investigation demonstrates safety, immunogenicity, MyCholTM

Language: Английский

Citations

6
Optimization of Enterotoxigenic Escherichia coli (ETEC) Outer Membrane Vesicles Production and Isolation Method for Vaccination Purposes DOI Creative Commons
Melibea Berzosa,

Alberto Delgado-López,

Juan M. Irache

et al.

Microorganisms, Journal Year: 2023, Volume and Issue: 11(8), P. 2088 - 2088

Published: Aug. 15, 2023

The study addresses Enterotoxigenic Escherichia coli (ETEC), a significant concern in low-income countries. Despite its prevalence, there is no licensed vaccine against ETEC. Bacterial vesicle-based vaccines are promising due to their safety and diverse virulence factors. However, cost-effective production requires enhancing vesicle yield while considering altered properties isolation methods. proposed method involves heat treatment ultrafiltration recover vesicles from bacterial cultures. Two types, collected heat-treated (HT-OMV) or untreated (NT-OMV) cultures, were compared. Vesicles isolated via alone (“complete”) with ultracentrifugation (“sediment”). Preliminary findings suggest complete HT-OMV suitable for an ETEC vaccine. They express important proteins (OmpA, OmpX, OmpW) factors (adhesin TibA). Sized optimally (50–200 nm) mucosal vaccination, they activate macrophages, inducing marker expression (CD40, MHCII, CD80, CD86) Th1/Th2 cytokine release (IL-6, MCP-1, TNF-α, IL12p70, IL-10). This confirms non-toxicity RAW 264.7 cells the vivo ability of generate IgG2a/IgG1 serum antibodies. Results promise vaccine, requiring further research on toxicity, pathogen-specific antibody detection, protective efficacy.

Language: Английский

Citations

3
Oral Immunogenicity of Enterotoxigenic Escherichia coli Outer Membrane Vesicles Encapsulated into Zein Nanoparticles Coated with a Gantrez® AN–Mannosamine Polymer Conjugate DOI Creative Commons
Melibea Berzosa, Alžběta Nemeškalová, Alba Calvo

et al.

Pharmaceutics, Journal Year: 2022, Volume and Issue: 14(1), P. 123 - 123

Published: Jan. 4, 2022

Enterotoxigenic Escherichia coli (ETEC) represents a major cause of morbidity and mortality in the human population. In particular, ETEC infections affect children under age five from low-middle income countries. However, there is no licensed vaccine against this pathogen. development challenging since pathotype expresses wide variety antigenically diverse virulence factors whose genes can be modified due to genetic plasticity. To overcome challenge, we propose use outer membrane vesicles (OMVs) isolated two clinical strains. these OMVs, proteomic studies revealed presence important immunogens, such as heat-labile toxin, colonization factors, adhesins mucinases. Furthermore, proved immunogenic after subcutaneous administration BALB/c mice. Since an enteropathogen, it necessary induce both systemic mucosal immunity. For purpose, vesicles, free or encapsulated zein nanoparticles coated with Gantrez®–mannosamine conjugate, were administered orally. Biodistribution showed that encapsulation OMVs delayed transit through gut. These results confirmed by vivo study, which OMV resulted higher levels specific antibodies IgG2a. Further are needed evaluate protection efficacy approach.

Language: Английский

Citations

5
Resposta adaptativa de Escherichia coli enterotoxigênica (ETEC) a concentrações subletais de óleos essenciais e seus compostos DOI Creative Commons
Victor Maximiliano Reis Tebaldi, Jonathan Neves de Carvalho Alves, Roberta Hilsdorf Píccoli

et al.

Cuadernos de Educación y Desarrollo, Journal Year: 2024, Volume and Issue: 16(2), P. e2561 - e2561

Published: Feb. 23, 2024

Os mecanismos de respostas ao estresse presentes em Escherichia coli são bem conhecidos, entretanto, pouco se sabe sobre a possível adaptação homóloga e heteróloga desse microrganismo aos óleos essenciais seus componentes majoritários. Assim, esse trabalho avaliou capacidade E. enterotoxigênica (ETEC) concentrações subletais cravo-da-índia, citronela canela eugenol, citral cinamaldeído. Após determinação das Concentrações Inibitórias Mínimas (CIM) Bactericidas (CBM) foi avaliada da bactéria. ETEC exposta (CIM/8) dos majoritários desenvolveu todos os tratamentos, com aumento CBM até 4 vezes. A heteróloga, utilizando-se cinamaldeído citral, ocorreu para ambos agentes estressores. Quando o as aumentaram vezes, exceto óleo cuja permaneceu inalterada. Já quando estressor cinamaldeído, observou-se antimicrobianos. Dessa forma, alerta-se possibilidade majoritários, utilizados inadequadas, promoverem tolerância esses antimicrobianos prejudicando controle dessa bactéria na indústria alimentícia.

Citations

0